drugset / Trial / NCT04541485
To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is designed to assess the safety and tolerability of single doses of DWRX2003 in COVID-19 patients.
Timeline
- Start
- 2020-12-04
- Primary completion
- 2021-03-03
- Completion
- 2021-03-23
Outcome
Outcome not reported
Stopped: “Enrolment was suspended since 09Dec2020 due to a lack of COVID-19 patients.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DWRX2003 | Unknown | 96 mg | Intramuscular |
| Subject | DWRX2003 | Unknown | 288 mg | Intramuscular |
| Subject | DWRX2003 | Unknown | 480 mg | Intramuscular |
| Subject | DWRX2003 | Unknown | 672 mg | Intramuscular |
| Subject | DWRX2003 | Unknown | 960 mg | Intramuscular |
Indications
No indication recorded.